维普期刊资源整合服务平台（V6.5）

30篇 您的检索式：作者名="Cheever MA"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	The prioritization of cancer antigens : a national cancer institute pilot project for the acceleration of translational research 显示文摘	Cheever MA Allison JP Fen-is AS	2009	Clin Cancer Res2009，15，17：	1
2	The prioritization of cancer antigens:a national cancer institute pilot project for the acceleration of translational research显示文摘	Cheever MA Allison JP Ferris AS	2009	Clin Cancer Res2009，15，17：	1
3	New directions in cel- lular therapy of cancer: A summary of the summit on cellular thera- py for cancer显示文摘	Stroncek DF Berger C Cheever MA ct al	2012	J Transl Med2012，10，1：	1
4	Human HER-2/neu protein immunization circumvents tolerance to rat neu:a vaccine strategy for 'self' tumour antigens显示文摘	Disis ML Shiota FM Cheever MA	1998	Immunology1998，93，2：	1
5	PROVENGE (Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine显示文摘	Cheever MA Higano CS		0，，11：	1
6	Provenge (sipuleucel-T) in prostate cancer the first FDA-approved therapeutic cancer vaccine 显示文摘	Cheever MA Higano CS	2011	Clin Cancer Res2011，17，11：	1
7	WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies 显示文摘	Rosenfeld C Cheever MA Gaiger A	2003	Leukemia2003，17，7：	1
8	HER-2/neu protein:a target for antigen-specific immunotherapy of human cancer显示文摘	Disis ML Cheever MA	1997	Adv Cancer Res1997，71，71：	1
9	WT1 in acute leukemia,chronic myelogenous leukemia and myelodysplastic syndrome:Therapeutic potential of WT1 targeted therapies显示文摘	Rosenfeld C Cheever MA Gaiger A	2003	Leukemia2003，17，7：	1
10	PROVENGE(Sipuleucel-T)in prostate canc-er:the first FDA-approved therapeutic cancer vaccine显示文摘	Cheever MA Higano CS		0，，：	1
11	Human HER-2/neu protein immunization circumvents tolerance to rat neu : a vaccine strategy for-self, tumourantigens 显示文摘	Disis ML Shiota FM Cheever MA	1998	Immunology1998，93，2：	1
12	Immunity to oncngenic proteins显示文摘	Cheever MA Disis ML Bernhard H	1995	Immunol Rev1995，145，：	1
13	Immunization of cancer patients with a HER- 2/neu, H/A - A2 peptide, p369 - 377, results in short - lived peptide - specific immunity 显示文摘	Knutson KL Schiffman K Cheever MA	2002	Clin Cancer Res2002，8，5：	1
14	Therapy with cultured T cells:principles revisited显示文摘	Cheever MA Chen W	1997	Immunol Rev1997，157，：	1
15	H-2 restriction of adoptive immunotherapy of advanced tumors 显示文摘	Greenberg PD Cheever MA Fefer A	1981	J Immunol1981，126，6：	1
16	Human HER 2/neu protein immunization cireumevents tolerance to rat neu:a vaccine strategy for ' self' tumour antigens显示文摘	Disis ML Shiota FM Cheever MA	1998	Immunol1998，93，：	1
17	Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-speeific immunity 显示文摘	Knutson KL Sehiffman K Cheever MA	2002	Clin Cancer Res2002，8，5：	1
18	The prioritization ofcancer antigens:a national cancer institute pilot project for theacceleration of translational显示文摘	Cheever MA Allison JP Ferris AS	2009	Res Clin Cancer Res2009，15，17：	1
19	Oncogenic Proteins as tumor antigens curr opin 显示文摘	Disis ML Cheever MA	1996	Immunology1996，8，：	1
20	Oncogenic proteins as tumor antigens 显示文摘	Disis ML Cheever MA	1996	Curr Opin Immunol1996，8，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示